DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
5.69
-0.03 (-0.52%)
May 21, 2026, 12:15 PM EDT - Market open

DiaMedica Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
9.799.787.628.166.164.88
Research & Development
26.9524.6119.0613.117.848.77
Total Operating Expenses
36.7434.426.6821.271413.65
Operating Income
-36.74-34.4-26.68-21.27-14-13.65
Total Non-Operating Income (Expense)
-1.66-3.32-4.53-3.86-0.71-0.16
Pretax Income
-35.07-32.74-24.41-19.34-13.65-13.56
Provision for Income Taxes
0.030.030.030.040.030.03
Net Income
-35.1-32.77-24.44-19.38-13.68-13.59
Net Income to Common
-35.1-32.77-24.44-19.38-13.68-13.59
Shares Outstanding (Basic)
504740332621
Shares Outstanding (Diluted)
504740332621
Shares Change (YoY)
19.42%16.28%24.07%23.16%27.29%32.48%
EPS (Basic)
-0.71-0.70-0.60-0.60-0.52-0.65
EPS (Diluted)
-0.71-0.70-0.60-0.60-0.52-0.65
Shares Outstanding
53.8853.7442.8237.9626.4426.44
Free Cash Flow
-31.03-29.1-22.1-18.75-11.59-12.27
Free Cash Flow Per Share
-0.62-0.62-0.55-0.58-0.44-0.59
EBITDA
-36.69-34.35-26.64-21.24-13.98-13.62
EBIT
-36.74-34.4-26.68-21.27-14-13.65
Effective Tax Rate
-0.08%-0.09%-0.12%-0.22%-0.21%-0.21%
Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q